The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis

被引：13

作者：

Dichtel, Laura E. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Neuroendocrine Unit, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

来源：

HEPATOLOGY | 2021年 / 74卷 / 04期

关键词：

D O I：

10.1002/hep.31886

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：2290 / 2292

页数：3

共 8 条

[1] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021 [J].

不详 .

DIABETES CARE, 2021, 44 :S111-S124

[2] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[3] Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway [J].

Gupta, Nitika Arora ;

Mells, Jamie ;

Dunham, Richard M. ;

Grakoui, Arash ;

Handy, Jeffrey ;

Saxena, Neeraj Kumar ;

Anania, Frank A. .

HEPATOLOGY, 2010, 51 (05) :1584-1592

[4] Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis [J].

Han, Ma Ai Thanda ;

Altayar, Osama ;

Hamdeh, Shadi ;

Takyar, Varun ;

Rotman, Yaron ;

Etzion, Ohad ;

Lefebvre, Eric ;

Safadi, Rifaat ;

Ratziu, Vlad ;

Prokop, Larry J. ;

Murad, Mohammad Hassan ;

Noureddin, Mazen .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (04) :616-+

[5]

Marso SP, 2016, NEW ENGL J MED, V375, P311, DOI [10.1056/NEJMoa1603827, 10.1056/NEJMc1615712]

[6] Are all GLP-1 agonists equal in the treatment of type 2 diabetes? [J].

Nauck, Michael A. ;

Meier, Juris J. .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (06) :R211-R234

[7] A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis [J].

Newsome, Philip N. ;

Buchholtz, Kristine ;

Cusi, Kenneth ;

Linder, Martin ;

Okanoue, Takeshi ;

Ratziu, Vlad ;

Sanyal, Arun J. ;

Sejling, Anne-Sophie ;

Harrison, Stephen A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1113-1124

[8] Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis [J].

Vilar-Gomez, Eduardo ;

Martinez-Perez, Yadina ;

Calzadilla-Bertot, Luis ;

Torres-Gonzalez, Ana ;

Gra-Oramas, Bienvenido ;

Gonzalez-Fabian, Licet ;

Friedman, Scott L. ;

Diago, Moises ;

Romero-Gomez, Manuel .

GASTROENTEROLOGY, 2015, 149 (02) :367-+

← 1 →